Pacer Advisors Inc. Sells 45,766 Shares of Theravance Biopharma, Inc. $TBPH

Pacer Advisors Inc. cut its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 13.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 293,192 shares of the biopharmaceutical company’s stock after selling 45,766 shares during the period. Pacer Advisors Inc.’s holdings in Theravance Biopharma were worth $4,759,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quarry LP purchased a new position in shares of Theravance Biopharma in the 3rd quarter worth $26,000. Mirae Asset Global Investments Co. Ltd. increased its position in Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares during the period. CIBC Private Wealth Group LLC boosted its position in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 781 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Stock Up 0.1%

TBPH stock opened at $16.90 on Thursday. The business’s 50-day moving average price is $16.74 and its 200-day moving average price is $16.95. The stock has a market cap of $871.19 million, a P/E ratio of 7.68 and a beta of 0.19. Theravance Biopharma, Inc. has a twelve month low of $11.05 and a twelve month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of $17.70 million for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, equities research analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on TBPH. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their target price for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Finally, BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.40.

Insider Activity

In related news, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares of the company’s stock, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider owned 9,174,453 shares of the company’s stock, valued at $155,965,701. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 350,011 shares of company stock worth $6,008,309 over the last ninety days. Insiders own 7.65% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.